Table 3.
Characteristics of Patients in the Non-New CVD Onset Group and New CVD Onset Group.
| Variable (unit: reference value) | Non-new CVD onset group (n = 95) |
New CVD onset group (n = 53) |
p-value |
|---|---|---|---|
| Male/Female | 55/40 | 30/23 | 1.0 |
| Age (years) | 68.5 ± 12.4 | 68.7 ± 9.7 | 0.91 |
| Body Mass Index (kg/m2) | 22.9 ± 2.9 | 23.2 ± 3.1 | 0.44 |
| Duration on HD (months) | 107.7 ± 91.4 | 70.2 ± 76.9 | 0.02 |
| Patients with Diabetes | 33 (34.7%) | 21 (39.6%) | 0.60 |
| Patients with a history of CVD | 56 (58.9%) | 22 (41.5%) | 0.059 |
| Patients taking phosphate binders | 67 (70.5%) | 29 (54.7%) | 0.07 |
| Patients taking antihyperlipidemic drugs | 4 (4.2%) | 4 (7.5%) | 0.46 |
| Patients taking antihypertensive drugs | 40 (42.1%) | 23 (43.4%) | 0.67 |
| FIF (days/week) | 0.13 | ||
| 0-1 day | 24 (25.3%) | 8 (15.1%) | |
| 2-3 days | 38 (40.0%) | 30 (56.6%) | |
| 4-5 days | 22 (23.2%) | 7 (13.2%) | |
| everyday | 11 (11.6%) | 8 (15.1%) | |
| Clinical data | |||
| WBC (/μL: 3100-8400) | 5235 ± 1523 | 4775 ± 1992 | 0.11 |
| Hemoglobin (g/dL: 11.4-16.6) | 10.46 ± 1.00 | 10.19 ± 1.23 | 0.60 |
| CRP (mg/L: 0.3-1.7) | 0.38 ± 0.66 | 0.26 ± 0.50 | 0.28 |
| Albumin (g/L: 3.8-5.3) | 3.48 ± 0.21 | 3.32 ± 0.27 | 0.36 |
| P (mg/L: 2.5-4.5) | 5.71 ± 1.61 | 5.58 ± 1.28 | 0.64 |
| K (mEq/L: 3.5-5.0) | 4.80 ± 0.74 | 5.03 ± 0.91 | 0.10 |
| TG (mg/dl: 20-149) | 98.1 ± 64.5 | 96.9 ± 53.2 | 0.91 |
| T-Chol (mg/dl: 140-199) | 143.2 ± 33.7 | 143.7 ± 30.9 | 0.93 |
| HDL-c (mg/dl: ≥40) | 41.3 ± 13.0 | 43.5 ± 12.3 | 0.32 |
| LDL-c (mg/dl: 60-119) | 82.5 ± 24.6 | 78.9 ± 27.2 | 0.42 |
| DHA (μg/mL: 54.8-240.3) | 88.3 ± 32.2 | 99.4 ± 34.7 | 0.053 |
| EPA (μg/mL: 10.2-142.3) | 50.4 ± 34.2 | 56.4 ± 28.5 | 0.28 |
| ARA (μg/mL: 135.7-335.3) | 143.1 ± 38.2 | 145.2 ± 44.9 | 0.77 |